Author:
Kouvari Matina,Valenzuela-Vallejo Laura,Guatibonza-Garcia Valentina,Polyzos Stergios A.,Deng Yixiang,Kokkorakis Michail,Agraz Melih,Mylonakis Sophia C.,Katsarou Angeliki,Verrastro Ornella,Markakis Georgios,Eslam Mohammed,Papatheodoridis Georgios,George Jacob,Mingrone Geltrude,Mantzoros Christos S.
Funder
Boehringer Ingelheim Corp USA
Boehringer Ingelheim
Merck Sharp and Dohme
Massachusetts Life Sciences Center
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference45 articles.
1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018
2. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach;Le;Clin Mol Hepatol,2022
3. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes;Godoy-Matos;Diabetol Metab Syndr,2020
4. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD) registry;Younossi;Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc,2022
5. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献